Boston ScientificNYSE: BSX

Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph Fitzgerald - Executive Vice President and Group President, Cardiology Lance Bates - Senior Vice President and President Janar Sathananthan - Chief Medical Officer Kenneth Stein - Chief Medical Officer Conference Call Participants Operator Good day, and welcome to the Boston Scientific Cardiology Business Update. [Operator Instructions] Please note, this event is being recorded.

No matter if you focus on value, growth, or momentum investing, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key benefits of the Zacks Premium research service.

BSX's Endoscopy division in MedSurg is benefiting from high global demand for its wide variety of gastrointestinal and pulmonary treatment solutions.

Boston Scientific, a company that makes medical devices, is expected to keep growing its profits over the next few years. This positive outlook is supported by its strong history, good profit margins, product pipeline, and smart use of capital. Although other analysts on Seeking Alpha have given it a Hold rating this year, I believe it deserves a Buy rating and anticipate a nearly 15% increase in its price over the next year.

Boston Scientific (BSX) has strong growth characteristics that may enable it to significantly exceed market performance.

These five stocks have delivered returns in the double digits so far this year. Even with the recent increase, they still have the potential for further double-digit growth in the near future.

On Wednesday, Boston Scientific Corporation BSX announced the results of the main goal of the ACURATE IDE trial for the ACURATE neo2 Aortic Valve System. This trial focused on patients with severe, symptomatic aortic stenosis who are at risk of needing open-heart surgery.

The Zacks Earnings ESP is an excellent tool for identifying possible earnings surprises. Investors should consider using it right now.

This is a comparison of how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have done in relation to their industry this year.